ClinicalTrials.gg
Active, not recruitingNCT07109297Updated Mar 23, 2026

Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India

A Phase 4 interventional study of Nirsevimab in RSV Immunization, sponsored by Sanofi. Active, not recruiting at 7 sites in India. Open to participants aged 0 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Sanofi · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
0 Months to 24 Months
Sex
All
01

Study summary

The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Read the detailed description

Study duration: up to 16 months, including 10 months of enrollment and 6 months of follow-up

  • Treatment duration: 1 day; 1 intramuscular (IM) injection
  • Visit frequency:

    • 1 in-person visit for immunization (Visit [V] 01) at Day (D) 1.
    • 3 phone call visits (V2, V3 and V4) at D31 (+ 14 days), D91 (+ 14 days) and D181 (+14 days) respectively.
02

Conditions studied

  • RSV Immunization
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Neonates and infants aged 0 to 12 months on the day of inclusion and born during or entering their first RSV season OR children up to 24 months of age on the day of inclusion who remain vulnerable to severe RSV disease through their second RSV season

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Known thrombocytopenia, as reported by the parent(s)/legally acceptable representative(s), contraindicating intramuscular injection
  • Known bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Active LRTI on the day of study intervention administration
  • Active RSV infection on the day of study intervention administration
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
  • Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine in the same RSV season than inclusion in the study
  • Mother of the participant was administered an RSV vaccine during her pregnancy with the participant
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of any drug in the last 30 days prior to the inclusion in the study
  • Participation at the time of study enrollment or in the 4 weeks preceding the study intervention administration or planned participation during the present study period, in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Nirsevimab

    Participants will receive: * 1 intramuscular (IM) injection for neonates and infants aged 0 to 12 months born or entering their first RSV season at Day 01 * 2 IM injections for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season at Day 01

    Biological: Nirsevimab

Interventions

  • BiologicalNirsevimab

    Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular

    Also known as: 526, Beyfortus®

06

What researchers measure

Primary outcomes

  1. Presence of immediate adverse events (AEs)

    Number of participants experiencing immediate AEs

    Time frame: Within 30 minutes after immunization

  2. Presence of non-serious AEs

    Number of participants experiencing non-serious AEs

    Time frame: From Day 01 through Day 31

  3. Presence of adverse events of special interest (AESIs) throughout the study

    Number of participants experiencing AESIs

    Time frame: Throughout the study (approximately 6 months)

  4. Presence of medically attended adverse events (MAAEs) throughout the study

    Number of participants experiencing MAAEs

    Time frame: Throughout the study (approximately 6 months)

  5. Presence of serious adverse events (SAEs) throughout the study

    Number of participants experiencing SAEs

    Time frame: Throughout the study (approximately 6 months)

Secondary outcomes

  1. Incidence of medically attended lower respiratory tract infection (LRTI) (outpatient and inpatient) due to reverse transcription--polymerase chain reaction (RT-PCR) confirmed RSV

    Incidence of medically attended LRTI (outpatient and inpatient) due to reverse transcription--polymerase chain reaction (RT-PCR) confirmed RSV

    Time frame: Through 180 days after dosing

  2. Incidence of LRTI hospitalizations due to RT-PCR confirmed RSV through 180 days after dosing

    Incidence of LRTI hospitalizations due to RT-PCR confirmed RSV through 180 days after dosing

    Time frame: Through 180 days after dosing

07

Study locations

7 sites
  • Investigational Site Number : 3560002
    Bengaluru, 560011, India
  • Investigational Site Number : 3560008
    Jaipur, 302007, India
  • Investigational Site Number : 3560003
    Kolkata, 700017, India
  • Investigational Site Number : 3560007
    Nagpur, 441108, India
  • Investigational Site Number : 3560001
    New Delhi, 110060, India
  • Investigational Site Number : 3560004
    Pune, 411007, India
  • Investigational Site Number : 3560006
    Vizianagaram, 535003, India
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07109297
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Jul 31, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Mar 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion